New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer

por Horn, Peer, Jakobsen, Erik Hugger, Madsen, Jonna Skov, Brandslund, Ivan
Publicado 2014

Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification

por Sørensen, Patricia Diana, Andersen, Rikke Fredslund, Pallisgaard, Niels, Madsen, Jonna Skov, Jakobsen, Erik Hugger, Brandslund, Ivan
Publicado 2015

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase...

por Kümler, Iben, Balslev, Eva, Stenvang, Jan, Brünner, Nils, Ejlertsen, Bent, Jakobsen, Erik Hugger, Nielsen, Dorte Lisbet
Publicado 2019

Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study

por Kjær, Ina Mathilde, Olsen, Dorte Aalund, Brandslund, Ivan, Bechmann, Troels, Jakobsen, Erik Hugger, Bogh, Søren Bie, Madsen, Jonna Skov
Publicado 2020

Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer

por Kjær, Ina Mathilde, Olsen, Dorte Aalund, Brandslund, Ivan, Bechmann, Troels, Jakobsen, Erik Hugger, Bogh, Søren Bie, Madsen, Jonna Skov
Publicado 2020

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA

por Kjær, Ina Mathilde, Kahns, Søren, Timm, Signe, Andersen, Rikke Fredslund, Madsen, Jonna Skov, Jakobsen, Erik Hugger, Tabor, Tomasz Piotr, Jakobsen, Anders, Bechmann, Troels
Publicado 2023

Predicting brain metastases of breast cancer based on serum S100B and serum HER2

por BECHMANN, TROELS, MADSEN, JONNA SKOV, BRANDSLUND, IVAN, LUND, ERIK DALSGAARD, ORMSTRUP, TINA, JAKOBSEN, ERIK HUGGER, JYLLING, ANNE MARIE BAK, STEFFENSEN, KARINA DAHL, JAKOBSEN, ANDERS
Publicado 2013

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

por Røssevold, Andreas Hagen, Andresen, Nikolai Kragøe, Bjerre, Christina Annette, Gilje, Bjørnar, Jakobsen, Erik Hugger, Raj, Sunil Xavier, Falk, Ragnhild Sørum, Russnes, Hege Giercksky, Jahr, Thea, Mathiesen, Randi Ruud, Lømo, Jon, Garred, Øystein, Chauhan, Sudhir Kumar, Lereim, Ragnhild Reehorst, Dunn, Claire, Naume, Bjørn, Kyte, Jon Amund
Publicado 2022

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded...

por Buhl, Anna Sofie Kappel, Christensen, Troels Dreier, Christensen, Ib Jarle, Nelausen, Knud Mejer, Balslev, Eva, Knoop, Ann Søegaard, Brix, Eva Harder, Svensson, Else, Glavicic, Vesna, Luczak, Adam, Langkjer, Sven Tyge, Linnet, Søren, Jakobsen, Erik Hugger, Bogovic, Jurij, Ejlertsen, Bent, Rasmussen, Annie, Hansen, Anker, Knudsen, Steen, Nielsen, Dorte, Jensen, Peter Buhl
Publicado 2018

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

por Chia, Stephen K. L., Martin, Miguel, Holmes, Frankie A., Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Mansi, Janine, Barrios, Carlos H., Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Kim, Sung-Bae, Jakobsen, Erik Hugger, Harvey, Vernon, Robert, Nicholas, Smith, John, Harker, Graydon, Zhang, Bo, Eli, Lisa D., Ye, Yining, Lalani, Alshad S., Buyse, Marc, Chan, Arlene
Publicado 2019